** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23
** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg
** Adds, Eli Lilly's LLY.N orforglipron also in spotlight
** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say
** YTD, NOVOb is down 16.7%
** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch
** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure
** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar
** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601
(Reporting by Anna Pruchnicka)
((anna.pruchnicka@tr.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。